CoChat

mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition

Open access
Limon, Jose J., So, Lomon, Jellbauer, Stefan, Chiu, Honyin, Corado, Juana, Sykes, Stephen M., Raffatellu, Manuela, Fruman, David A. · 2014 · Proceedings of the National Academy of Sciences

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Abstract

Significance: Rapamycin is an immunosuppressive drug that partially inhibits the cellular kinase mammalian target of rapamycin (mTOR). This study uncovers previously unidentified mechanisms of mTOR signaling in B cells. Antigen recognition and other signals activate mTOR, a central driver of lymphocyte proliferation and differentiation. However, mTOR forms two protein complexes (mTORC1 and mTORC2) whose roles in B-cell differentiation are poorly defined. We found that a new class of ATP-competitive mTOR kinase inhibitors (TOR-KIs) can augment antibody class switching at concentrations that partially inhibit mTOR activity. Mechanistic studies indicate that mTORC1 loss suppresses, whereas mTORC2 loss promotes, class switching. The dominant effect of TOR-KIs is to promote switching through mTORC2 inhibition. These findings establish distinct immunomodulatory activity of TOR-KIs compared with the canonical mTOR inhibitor rapamycin.

Overview

Integrity signals

Registry

Crossref · 10.1073/pnas.1407104111

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 36 references

Cited by

See all 86

Metadata

Authors
Limon, J. J., So, L., Jellbauer, S., Chiu, H., Corado, J., Sykes, S. M., Raffatellu, M., & Fruman, D. A.
Affiliations
  • Department of Molecular Biology & Biochemistry,
  • University of California, Irvine (US)
  • Fox Chase Cancer Center (US)
Venue
Proceedings of the National Academy of Sciences
Published
2014-11-10
Volume
111
Issue
47
Pages
E5076-85
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2002368085
Cited by
76
References
36
Citations by year
2026: 5 · 2025: 8 · 2024: 2 · 2023: 8 · 2022: 6 · 2021: 3 · 2020: 6 · 2019: 2 · 2018: 8 · 2017: 17 · 2016: 9 · 2015: 2
FWCI
4.26
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
Funders
  • National Institutes of Health
  • National Cancer Institute (P30 CA 62203, R00CA158461, P30CA062203)
  • National Institute of Allergy and Infectious Diseases (R21AI099656, R01AI083663, T32AI060573, R03AI085462)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
Keywords
mTOR inhibitors, mTORC1, mTORC2, antibody class switching, B cells, FOXO transcription factors, AZD8055, rapamycin, germinal center, somatic hypermutation, B cell differentiation, high-affinity antibodies, vaccination
MeSH terms
Mechanistic Target of Rapamycin Complex 2, Allosteric Regulation, Animals, Immunoglobulin G, Mice, Inbred C57BL, Immunoglobulin Class Switching, Sirolimus, Multiprotein Complexes, Protein Kinase Inhibitors, Mice, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition. https://app.cochat.ai/papers/10.1073/pnas.1407104111
The paper
Limon, J. J., So, L., Jellbauer, S., Chiu, H., Corado, J., Sykes, S. M., Raffatellu, M., & Fruman, D. A. (2014). mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1407104111

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.